Pre-order Enquiry
Request Free Sample
Global and China Arbidol Tablets(COVID-19) Market Insights, Forecast to 2027
SKU ID : QYR-19242633 | Publishing Date : 28-Sep-2021 | No. of pages : 125
Arbidol Hydrochloride as known as Arbidol, is an antiviral treatment for influenza infection.
In February 2020, Li Lanjuan, an expert of the National Health Commission of China, proposed using Arbidol (umifenovir) together with darunavir as a potential treatment during the 2019–20 coronavirus outbreak. Chinese experts claim that preliminary tests had shown that arbidol and darunavir could inhibit replication of the virus. However, later studies showed that it did not show any efficacy in treating the Covid-19 disease. However usage by itself as a post-exposure prophylaxis (PEP) of Covid-19 transmission has been demonstrating positive results though further research is still warranted.
Market Analysis and Insights: Global and China Arbidol Tablets(COVID-19) Market
This report focuses on global and China Arbidol Tablets(COVID-19) market.
In 2020, the global Arbidol Tablets(COVID-19) market size was US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% during 2021-2027. In China the Arbidol Tablets(COVID-19) market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.
Global Arbidol Tablets(COVID-19) Scope and Market Size
Arbidol Tablets(COVID-19) market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Arbidol Tablets(COVID-19) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For China market, this report focuses on the Arbidol Tablets(COVID-19) market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in China.
Segment by Type
50mg
100mg
Segment by Application
Anti Influenza Virus
COVID-19
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
JSC Pharmstandard
Jiangsu Wuzhong Pharmaceutical
CSPC Ouyi Pharmaceutical
Simcere Pharmaceutical
In February 2020, Li Lanjuan, an expert of the National Health Commission of China, proposed using Arbidol (umifenovir) together with darunavir as a potential treatment during the 2019–20 coronavirus outbreak. Chinese experts claim that preliminary tests had shown that arbidol and darunavir could inhibit replication of the virus. However, later studies showed that it did not show any efficacy in treating the Covid-19 disease. However usage by itself as a post-exposure prophylaxis (PEP) of Covid-19 transmission has been demonstrating positive results though further research is still warranted.
Market Analysis and Insights: Global and China Arbidol Tablets(COVID-19) Market
This report focuses on global and China Arbidol Tablets(COVID-19) market.
In 2020, the global Arbidol Tablets(COVID-19) market size was US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% during 2021-2027. In China the Arbidol Tablets(COVID-19) market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.
Global Arbidol Tablets(COVID-19) Scope and Market Size
Arbidol Tablets(COVID-19) market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Arbidol Tablets(COVID-19) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For China market, this report focuses on the Arbidol Tablets(COVID-19) market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in China.
Segment by Type
50mg
100mg
Segment by Application
Anti Influenza Virus
COVID-19
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
JSC Pharmstandard
Jiangsu Wuzhong Pharmaceutical
CSPC Ouyi Pharmaceutical
Simcere Pharmaceutical
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Request Sample
Request Discount
